Inactivation Or Attenuation; Producing Viral Subunits Patents (Class 435/236)
  • Patent number: 9623095
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 18, 2017
    Assignee: CureVac AG
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Patent number: 9249191
    Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: February 2, 2016
    Assignee: VLP Therapeutics, LLC
    Inventors: Ryuji Ueno, Wataru Akahata
  • Patent number: 9187732
    Abstract: The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 17, 2015
    Assignee: Baxalta GmbH
    Inventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
  • Patent number: 9125870
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: September 8, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
  • Patent number: 9034343
    Abstract: The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 19, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins, Sheila Nolan
  • Publication number: 20150126410
    Abstract: The invention relates in a first embodiment to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein said adenoviruses are generated in a production cell, the method comprising the steps of: (a) expressing in said production cell an adenoviral pIX polypeptide from a nucleic acid sequence encoding said adenoviral pIX polypeptide under the control of (i) at least a minimal endogenous pIX promoter and a heterologous promoter; or (ii) a heterologous promoter; and (b) expressing in said production cell the elements necessary for the production and assembly of said adenoviruses from corresponding coding sequences, thereby increasing the yield of said adenoviruses generated in said production cell in comparison to the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region generated in said production cell in the absence of said nucleic acid sequence encoding said adenoviral pIX polypeptide.
    Type: Application
    Filed: July 4, 2013
    Publication date: May 7, 2015
    Inventors: Christian Thirion, Zsolt Ruzsics
  • Publication number: 20150118732
    Abstract: Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 30, 2015
    Inventors: Peter L. Collins, Cindy L. Luongo, Ursula J. Buchholz, Brian R. Murphy
  • Publication number: 20150118201
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 30, 2015
    Inventors: Xiao Xiao, Lin Yang
  • Patent number: 9012618
    Abstract: The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: April 21, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Nancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
  • Patent number: 9011876
    Abstract: The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary K. Yagodich, Michael P. Citron, Daniel J. Distefano, Daniel L. Krah, Xiaoping Liang
  • Publication number: 20150104830
    Abstract: The invention provides a process for generating an avian cell line of duck origin by a process comprising: —cultivating embryonic avian cells in cell culture medium, preferably comprising fetal calf serum (FBS) for more than 40 passages while reducing the concentration of FBS to 1-2% vol/vol FBS, —transferring passaged cells into cell culture medium having 0% FBS, —resulting in the generation of a non-embryonic avian cell line suitable for non-adherent growth, i.e. for growth in suspended culture.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 16, 2015
    Inventors: Manfred Wirth, Lijing Sun, Zhiguo Su, Roland Riebe, Jaeger Volker, Nadine Konisch
  • Patent number: 8992939
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 31, 2015
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margret Nathan, Thomas Kort, Robin Robinson
  • Patent number: 8993229
    Abstract: A method for extracting and distinguishing infectious norovirus from inactive norovirus using a solid support conjugated with a glycoprotein moiety capable of binding infectious norovirus wherein the presence of infectious norovirus is determined using RT-PCR after elution of the infectious norovirus from the solid support.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: David H. Kingsley
  • Patent number: 8974797
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: March 10, 2015
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Publication number: 20150064214
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 5, 2015
    Applicant: The USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Publication number: 20150056235
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 26, 2015
    Inventors: PATTI CYNTHIA CRAWFORD, PAUL J. GIBBS, EDWARD J. DUBOVI, RUBEN OMAR DONIS, JACQUELINE KATZ, ALEXANDER I. KLIMOV, NALLAKANNU P. LAKSHMANAN, MELISSA ANNE LUM, DANIEL GHISLENA EMIEL GOOVAERTS, MARK WILLIAM MELLENCAMP, NANCY J. COX, WILLIAM L. CASTLEMAN
  • Publication number: 20150050243
    Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Inventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
  • Publication number: 20150050308
    Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 19, 2015
    Inventor: Cornelia Maria van der Hoek
  • Patent number: 8951537
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 10, 2015
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 8940517
    Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: January 27, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Graninger, Martin Kaliwoda
  • Publication number: 20150024038
    Abstract: The invention is directed to immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 22, 2015
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Publication number: 20150017127
    Abstract: Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 15, 2015
    Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner, Colin Powers
  • Patent number: 8916175
    Abstract: Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: December 23, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Jeffrey I. Cohen, Edward M. Cox, Jr., Lesley M. Pesnicak
  • Patent number: 8916172
    Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: December 23, 2014
    Assignees: Emory University, National Institute of Allergy and Infectious Diseases (NIAID), The United States of America, as represented by the Department of Health and Human Services
    Inventors: Bernard Moss, Linda Wyatt, Patricia Earl, Harriet L. Robinson
  • Patent number: 8911975
    Abstract: The present invention discloses a cell system, as a host cell to be infected with an F gene-deficient virus, which can constitutively and stably express the F protein, and a method for producing an F gene-deficient virus by utilizing the cell. A non-proliferative human parainfluenza type 2 virus vector is produced by co-culturing an F gene-deficient human parainfluenza type 2 virus with a Vero cell having the F gene of human parainfluenza type 2 virus in such a manner that the F gene is non-inducibly expressed, and isolating viral particles from a culture supernatant.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: December 16, 2014
    Assignees: Mie University, BioComo Inc.
    Inventors: Masayuki Fukumura, Mitsuo Kawano, Tetsuya Nosaka, Junpei Ohtsuka
  • Publication number: 20140363469
    Abstract: The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microRNA binding sites within the viral target sequence of the pathogen.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 11, 2014
    Inventors: Rachel Meyers, Brian Bettencourt, Jamie Evan Wong, John M. Maraganore
  • Publication number: 20140356930
    Abstract: This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer.
    Type: Application
    Filed: June 3, 2013
    Publication date: December 4, 2014
    Inventor: Hossein A. Ghanbari
  • Publication number: 20140356962
    Abstract: A novel and stable attenuated poliovirus is produced by engineering an indigenous replication element (cre), into the 5? non-translated genomic region (with inactivation of the native ere element located in the coding region of 2C (mono-crePV), and replacing the nucleic acid sequence of all or part of the capsid coding region (PI) with a substitute PI coding region having reduced codon pair bias. The stably attenuated poliovirus is effective for vaccines and immunization.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 4, 2014
    Inventors: Eckard Wimmer, Jeronimo Cello, Ying Liu
  • Patent number: 8895026
    Abstract: The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Erns glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well to a method of attenuating a pestivirus comprising the step of modifying the Erns glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Erns glycoprotein.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Gregor Meyers, Birke Andrea Tews, Eva-Maria Schuermann
  • Patent number: 8895286
    Abstract: This invention relates to attenuated pestiviruses characterized in that their enzymatic activity residing in glycoprotein ERNS is inactivated, as well as methods of preparing, using and detecting these pestiviruses.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventor: Gregor Meyers
  • Publication number: 20140341848
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: RIBOSCIENCE LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • Publication number: 20140341908
    Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 20, 2014
    Applicant: INSTITUTE FOR SYSTEMS BIOLOGY
    Inventors: Carrie M. ROSENBERGER, Alan ADEREM
  • Publication number: 20140341941
    Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 20, 2014
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: DAVID B. WEINER, JIAN YAN
  • Publication number: 20140341948
    Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 20, 2014
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
  • Patent number: 8889398
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: November 18, 2014
    Assignee: Viroblock SA
    Inventors: Thierry Pelet, Francesca A. Wallach
  • Publication number: 20140335111
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 13, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Mathew P. Morrow
  • Publication number: 20140322270
    Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: CYNTHIA K. LEE, THOMAS P. MONATH, PATRICK M. GUERTIN, EDWARD G. HAYMAN
  • Patent number: 8859240
    Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
  • Patent number: 8859231
    Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignee: Wyeth LLC
    Inventors: Jose M. Galarza, Theresa E. Latham
  • Publication number: 20140302088
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 9, 2014
    Applicants: The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.
    Inventors: Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
  • Publication number: 20140302077
    Abstract: Provided are live attenuated influenza A and B viruses as well as a composition, influenza A and B genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza A or B virus and a use of the influenza viruses as a vaccine. An influenza A virus contains a NP-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of SEQ ID No: 1. A PA gene includes a silent mutation at one or more positions corresponding to a position selected from nucleotides 2100 and 2103 of SEQ ID No: 3.
    Type: Application
    Filed: August 28, 2012
    Publication date: October 9, 2014
    Applicant: Westfaelische Wilhelms-Universitaet Munester
    Inventors: Darisuren Anhlan, Christoph Scholtissek, Stephan Ludwig
  • Publication number: 20140302091
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Application
    Filed: November 18, 2011
    Publication date: October 9, 2014
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
  • Publication number: 20140286980
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length TTV genomes that can replicate efficiently in host animals and tissue culture.
    Type: Application
    Filed: May 24, 2012
    Publication date: September 25, 2014
    Applicant: ZOETIS LLC
    Inventor: Jacqueline Gayle Marx
  • Publication number: 20140255447
    Abstract: The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 11, 2014
    Applicant: BIOMUNE COMPANY
    Inventors: SHARAD DEVIDASRAO SAWARKAR, CHRISTOPHER PATRICK GULLY
  • Publication number: 20140255445
    Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.
    Type: Application
    Filed: January 24, 2014
    Publication date: September 11, 2014
    Applicant: L'Universite Pierre Et Marie Curie
    Inventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
  • Patent number: 8828406
    Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: September 9, 2014
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
  • Patent number: 8822192
    Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: September 2, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
  • Patent number: 8821889
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Publication number: 20140242670
    Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: Crucell Holland B.V.
    Inventor: John A. Lewis
  • Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai